【摘要】 目的:观察依达拉奉对急性脑梗死患者血清溶血磷脂酸(lysophosphatidic acid,LPA)、血浆酸性磷脂酸(acidity phosphatidic acid,AP)含量的影响及临床疗效。方法:选择急性脑梗死患者200例,随机分为依达拉奉治疗组(137例)和对照组(63例)。治疗组在对照组治疗的基础上,加用依达拉奉30mg静脉滴注,2次/d,共14d。分别于治疗前和治疗后1、2、3、7、14、21d取静脉血4mL测定AP、LPA水平,并在入院时、治疗7d、14d、1个月进行神经功能缺损(CSS)评定,并在3个月、半年进行日常生活能力量表(ADL)评定,了解依达拉奉的治疗效果。结果:对照组与依达拉奉组治疗14d后LPA、AP水平均较治疗前显著降低(P<0.01),CSS、ADL评分亦显著改善(P<0.05),与对照组相比,依达拉奉组上述指标改善更明显(P<0.01)。结论:依达拉奉能降低血清LPA、AP的水平,清除自由基,改善脑梗死的预后。更多还原

【Abstract】 Objective: To investigate the effect of Edaravone on the concentrations of acidic phosphatidic acid(AP) and lysophosphatidic acid(LPA) in serum and its clinical efficacy in patients with cerebral infarction.Methods: Patients with acute cerebral infarction were randomly assigned to Edaravone group(n=137) and control group(n=63).Edaravone(30 mg) was used as intravenous drip twice a day for 14 days in the Edaravone group besides the treatment as in the control group.Venous blood samples(4 mL) were taken to measure the levels of AP and LPA before and after treatment.The CSS were evaluated before treatment and at the 7th,14th and 30th day respectively after treatments,and the Activities of Daily Living Scale(ADL) were evaluated at the recruitment,the 3rd and 6th month respectively of the treatments.Results: The PA and LPA levels in both groups decreased after 14 days of treatment(P<0.01),and the CSS and ADL scores also improved in both groups(P<0.05).However,a marked improvement of the above indexes was observed in the Edaravone group compared with the control group(P<0.01).Conclusion: Edaravone can decrease AP and LPA in serum,suppress free radicals and improve the prognosis of cerebral infarction.更多还原